Warning: The NCBI web site requires JavaScript to function. more...
Genetic background influences murine prostate gene expression: implications for cancer phenotypes.
Bianchi-Frias D, Pritchard C, Mecham BH, Coleman IM, Nelson PS.
Genome Biol. 2007;8(6):R117.
Related citations
Final Report on Carcinogens Background Document for Styrene.
National Toxicology Program.
Rep Carcinog Backgr Doc. 2008 Sep;(8-5978):i-398.
Final Report on Carcinogens Background Document for Formaldehyde.
Rep Carcinog Backgr Doc. 2010 Jan;(10-5981):i-512.
Isolation and characterization of the major form of human MUC18 cDNA gene and correlation of MUC18 over-expression in prostate cancer cell lines and tissues with malignant progression.
Wu GJ, Wu MW, Wang SW, Liu Z, Qu P, Peng Q, Yang H, Varma VA, Sun QC, Petros JA, Lim SD, Amin MB.
Gene. 2001 Nov 14;279(1):17-31.
Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays.
Bubendorf L, Kolmer M, Kononen J, Koivisto P, Mousses S, Chen Y, Mahlamäki E, Schraml P, Moch H, Willi N, Elkahloun AG, Pretlow TG, Gasser TC, Mihatsch MJ, Sauter G, Kallioniemi OP.
J Natl Cancer Inst. 1999 Oct 20;91(20):1758-64.
Gene expression profile of mouse prostate tumors reveals dysregulations in major biological processes and identifies potential murine targets for preclinical development of human prostate cancer therapy.
Haram KM, Peltier HJ, Lu B, Bhasin M, Otu HH, Choy B, Regan M, Libermann TA, Latham GJ, Sanda MG, Arredouani MS.
Prostate. 2008 Oct 1;68(14):1517-30.
Alterations in gene expression profiles during prostate cancer progression: functional correlations to tumorigenicity and down-regulation of selenoprotein-P in mouse and human tumors.
Calvo A, Xiao N, Kang J, Best CJ, Leiva I, Emmert-Buck MR, Jorcyk C, Green JE.
Cancer Res. 2002 Sep 15;62(18):5325-35.
Involvement of the multiple tumor suppressor genes and 12-lipoxygenase in human prostate cancer. Therapeutic implications.
Gao X, Porter AT, Honn KV.
Adv Exp Med Biol. 1997;407:41-53. Review.
Differences in gene expression in prostate cancer, normal appearing prostate tissue adjacent to cancer and prostate tissue from cancer free organ donors.
Chandran UR, Dhir R, Ma C, Michalopoulos G, Becich M, Gilbertson J.
BMC Cancer. 2005 May 13;5:45.
The novel human MOST-1 (C8orf17) gene exhibits tissue specific expression, maps to chromosome 8q24.2, and is overexpressed/amplified in high grade cancers of the breast and prostate.
Tan JM, Tock EP, Chow VT.
Mol Pathol. 2003 Apr;56(2):109-15.
The presence of prostate-specific antigen-related genes in primates and the expression of recombinant human prostate-specific antigen in a transfected murine cell line.
Karr JF, Kantor JA, Hand PH, Eggensperger DL, Schlom J.
Cancer Res. 1995 Jun 1;55(11):2455-62.
Expression of a human cell adhesion molecule, MUC18, in prostate cancer cell lines and tissues.
Wu GJ, Varma VA, Wu MW, Wang SW, Qu P, Yang H, Petros JA, Lim SD, Amin MB.
Prostate. 2001 Sep 15;48(4):305-15.
Heat shock protein expression independently predicts clinical outcome in prostate cancer.
Cornford PA, Dodson AR, Parsons KF, Desmond AD, Woolfenden A, Fordham M, Neoptolemos JP, Ke Y, Foster CS.
Cancer Res. 2000 Dec 15;60(24):7099-105.
Conditional expression of human 15-lipoxygenase-1 in mouse prostate induces prostatic intraepithelial neoplasia: the FLiMP mouse model.
Kelavkar UP, Parwani AV, Shappell SB, Martin WD.
Neoplasia. 2006 Jun;8(6):510-22.
Molecular characterization of the Ggamma-globin-Tag transgenic mouse model of hormone refractory prostate cancer: comparison to human prostate cancer.
Calvo A, Perez-Stable C, Segura V, Catena R, Guruceaga E, Nguewa P, Blanco D, Parada L, Reiner T, Green JE.
Prostate. 2010 May 1;70(6):630-45.
Unopposed c-MYC expression in benign prostatic epithelium causes a cancer phenotype.
Williams K, Fernandez S, Stien X, Ishii K, Love HD, Lau YF, Roberts RL, Hayward SW.
Prostate. 2005 Jun 1;63(4):369-84.
Identification of prostate cancer modifier pathways using parental strain expression mapping.
Xu Q, Majumder PK, Ross K, Shim Y, Golub TR, Loda M, Sellers WR.
Proc Natl Acad Sci U S A. 2007 Nov 6;104(45):17771-6. Epub 2007 Oct 31.
Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.
Morgenbesser SD, McLaren RP, Richards B, Zhang M, Akmaev VR, Winter SF, Mineva ND, Kaplan-Lefko PJ, Foster BA, Cook BP, Dufault MR, Cao X, Wang CJ, Teicher BA, Klinger KW, Greenberg NM, Madden SL.
Prostate. 2007 Jan 1;67(1):83-106.
Gene expression profiling in R-flurbiprofen-treated prostate cancer: R-Flurbiprofen regulates prostate stem cell antigen through activation of AKT kinase.
Zemskova M, Wechter W, Bashkirova S, Chen CS, Reiter R, Lilly MB.
Biochem Pharmacol. 2006 Nov 15;72(10):1257-67. Epub 2006 Sep 1.
Elevated expression of 12/15-lipoxygenase and cyclooxygenase-2 in a transgenic mouse model of prostate carcinoma.
Shappell SB, Olson SJ, Hannah SE, Manning S, Roberts RL, Masumori N, Jisaka M, Boeglin WE, Vader V, Dave DS, Shook MF, Thomas TZ, Funk CD, Brash AR, Matusik RJ.
Cancer Res. 2003 May 1;63(9):2256-67.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on